Difference between revisions of "Benralizumab (Fasenra)"
Jump to navigation
Jump to search
m |
|||
| Line 7: | Line 7: | ||
==Patient Drug Information== | ==Patient Drug Information== | ||
| − | *[https:// | + | *[https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/3647bed4-ce91-4fe7-9bc5-32dbee73f80a/3647bed4-ce91-4fe7-9bc5-32dbee73f80a_viewable_rendition__v.pdf Benralizumab (Fasenra) Package Insert]<ref>[https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/3647bed4-ce91-4fe7-9bc5-32dbee73f80a/3647bed4-ce91-4fe7-9bc5-32dbee73f80a_viewable_rendition__v.pdf Benralizumab (Fasenra) Package Insert]</ref> |
==Also known as== | ==Also known as== | ||
Latest revision as of 16:42, 27 May 2021
No FDA approval for hematology/oncology conditions, at this time.
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Diseases for which it is used
Patient Drug Information
Also known as
- Brand names: Fasenra